

In addition; Applicants have added new claims 13-26. Support for new claims 13-26 may be found in the specification (e.g., on page 3, lines 5-11; page 9, line 31 to page 10, line 9; and page 13, lines 9-13) as well as in the originally filed claims. No new matter has been added by these claim amendments and claim additions.

Applicants attach Appendix A with the newly revised claims, primarily for the Examiner's convenience.

In addition, Applicants attach Appendix B which is a marked-up version of the changes made to the claims by the current amendment.

CONCLUSION


Applicants reserve the right to file subsequent applications claiming the non-elected subject matter and do not waive any of their rights or abandon any non-elected subject matter. It is believed that the foregoing amendment places this application now in condition for early action. Therefore, early and favorable action allowing pending claims 10 and 13-26 is respectfully solicited.

Respectfully submitted,



Sandy Zaradic
Sandy Zaradic, Ph.D.
Reg. No. 45,997
Patent Agent for Applicants
(908) 298-7221

SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
Fax: 908-298-5388



WHAT IS CLAIMED IS:

10. (amended) A method for treating an individual suffering from a wound comprising administering an effective amount of a lymphotactin (XCL1) to the individual, whereby administration of the lymphotactin (XCL1) accelerates wound healing.
13. (new) The method of claim 10, wherein the administering is in combination with a chemokine selected from the group consisting of IL-8 (CXCL8), MCP3 (CCL7), MCP1 (CCL2), MCP-2 (CCL8), RANTES (CCL5), MIG (CXCL9), and SDF-1.
14. (new) The method of claim 10, wherein the administering is in combination with another therapeutic.
15. (new) The method of claim 10, wherein the administering is by expression of a nucleic acid.
16. (new) The method of claim 10, wherein the wound is an acute wound.
17. (new) The method of claim 10, wherein the wound is a chronic wound.
18. (new) The method of claim 10, wherein the wound is a chronic ulcera.
19. (new) The method of claim 10, wherein the wound is a cutaneous wound.
20. (new) The method of claim 19, wherein the cutaneous wound is from skin loss from burn.
21. (new) The method of claim 10, wherein the wound is a non cutaneous wound.
22. (new) The method of claim 21, wherein the non cutaneous wound is from injury to a stromal tissue.
23. (new) The method of claim 21, wherein the non cutaneous wound is from a surgery.
24. (new) The method of claim 23, wherein the surgery is an abdominal surgery.
25. (new) The method of claim 23, wherein the surgery is a cartilage or a joint surgery.
26. (new) The method of claim 23, wherein the surgery is an oral surgery.



DX01342 US
FEBRUARY 2003

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Cancel claims 1-9, 11-12

Amend claim 10 as follows:

10. A method of accelerating wound healing for treating an individual suffering from a wound comprising administering to an individual suffering from a wound an effective amount of a chemokine selected from lymphotactin (XCL1), IL-8 (CXCL8), MCP3 (CCL7), MCP1 (CCL2), MCP-2 (CCL8), RANTES (CCL5), MIG (CXCL9), or SDF-1 to the individual, whereby administration of the lymphotactin (XCL1) accelerates wound healing.

Add new claims 13-26 as follows:

13. The method of claim 10, wherein the administering is in combination with a chemokine selected from the group consisting of IL-8 (CXCL8), MCP3 (CCL7), MCP1 (CCL2), MCP-2 (CCL8), RANTES (CCL5), MIG (CXCL9), and SDF-1.

14. The method of claim 10, wherein the administering is in combination with another therapeutic.

15. The method of claim 10, wherein the administering is by expression of a nucleic acid.

16. The method of claim 10, wherein the wound is an acute wound.

17. The method of claim 10, wherein the wound is a chronic wound.

18. The method of claim 10, wherein the wound is a chronic ulcer.

19. The method of claim 10, wherein the wound is a cutaneous wound.

20. The method of claim 19, wherein the cutaneous wound is from skin loss from burn.

21. The method of claim 10, wherein the wound is a non cutaneous wound.

22. The method of claim 21, wherein the non cutaneous wound is from injury to a stromal tissue.

23. The method of claim 21, wherein the non cutaneous wound is from a surgery.

24. The method of claim 23, wherein the surgery is an abdominal surgery.

25. The method of claim 23, wherein the surgery is a cartilage or a joint surgery.

26. The method of claim 23, wherein the surgery is an oral surgery.



Attorney Docket No.: DX01342

Serial No.: 09/995,534

Filing Date: November 27, 2001

Inventor: Homey et al.

PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

on February 26, 2003

Date

A handwritten signature of "Sandy Zaradic" over a solid horizontal line.

Signature

RECEIVED
MAR 06 2003
TECH CENTER 1600/2900

SANDY ZARADIC, Reg. No. 45,997

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents enclosed:

Transmittal Sheet - 1 page

Response to Restriction Requirement - 5 pages

Extension of Time - 1 page IN DUPLICATE

Certificate of Mailing - 1 page

Return Postcard

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.